April 4, 2018 | Posted by Team in Webinar |
PEAKS AB: The Fastest Path to Accurate Antibody Sequences
What challenges do you face in characterizing monoclonal antibodies (mAbs) at the molecular level? Whether it’s heterogeneity caused by truncation or glycation, or confounding isobaric amino acids, you’ve wished there was a better way.
Watch our webinar to learn about a novel, three-in-one solution for obtaining 100% accurate amino acid sequences for antibody proteins, powered by the PEAKS AB software.
You will learn about:
- Intact mass analysis of antibody proteins; why is it important?
- De novo antibody protein sequencing workflow used in PEAKS AB service: algorithm and experimental procedure
- Isoleucine and leucine differentiation by using EThcD fragmentation methods
About Our Speaker
Wen Zhang, Ph.D. is the Senior Application Scientist at Bioinformatics Solutions Inc. (BSI). With her rich experience in proteomics and MS data generation, processing and analysis, she joined BSI, where she now leads the antibody protein de novo sequencing projects. Her work includes intact mass, de novo sequencing, peptide mapping, post-translational modification, disulfide bond and N-linked glycan analyses.
February 5, 2018 | Posted by Team in News |
PALO ALTO, Calif., DATE – Science Exchange, the world’s leading enterprise platform for outsourced research and development services and acquisition of human biospecimens, announced today its partnership with Novaseek Research Inc., a health information technology for life sciences company.
Now thousands of researchers using Science Exchange have on-demand access to Novaseek’s Clinical Data Network for Research (CDNR) platform to procure biospecimens, with patient consent and authorization, and associated real-world clinical data in pursuit of accelerating medical innovation. Researchers can utilize the CDNR platform in support of discovery, translational medicine, observational and clinical studies while Science Exchange manages the contracting process and tracks analytics to report performance and process improvement.
“Our CDNR platform can help accelerate the long and costly research process by precisely identifying patient populations with highly specific characteristics, starting early in the development process and continuing throughout,” said Andrei Soran, CEO of Novaseek Research. “Our partnership with Science Exchange enables clinical researchers to focus on getting medicines to market faster while Science Exchange provides operational and service support.”
“The fastest path to novel platforms like Novaseek’s CDNR via Science Exchange helps our leading biopharma clients to accelerate the drug development process and get important medicines to market quickly,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are committed to including the best scientific providers on our platform, and Novaseek meets our stringent vetting criteria. By leveraging population analytics, they help streamline study design and free scientists to focus on innovation.”
About Novaseek
Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit www.novaseekresearch.com.
About CDNR
Novaseek’s award-winning, novel, cloud platform, the Clinical Data Network for Research (CDNR), easily interfaces with hospital data sources in real time. The CDNR enables researchers to define patient cohorts through population analytics and to access consented biospecimens and clinical data to advance translational medicine, clinical development and observational studies. CDNR enables the fulfillment of complex requests, such as the collection of biospecimens and data before and after specific treatments, without burdening patients with extra blood draws or extensive medical questionnaires. This approach allows more hospitals and patients to participate in supporting biomedical research.
Talk to the Novaseek team today about your biospecimen and clinical data needs — visit their storefront and request a quote with your Scope of Work.
September 20, 2017 | Posted by Team in Provider Spotlight |
By Natalie Foote, Director of Service Provider Operations, Science Exchange | www.scienceexchange.com
In this Provider Innovation Profile, we’re proud to feature Transcriptic, whose automated cellular and molecular biology platform enables scalable life science research with flexibility and precision.
Automation is a rapidly advancing area of biotechnology, and Science Exchange hopes to give our researchers access to unique robotics platforms while helping them save on equipment costs and manage laboratory space limitations.
Transcriptic’s robotic cloud lab paradigm means biologists can be running experiments on the other side of the planet from their lab, leveraging a bank of robotic workcells for massive experimentation.
Transcriptic frees researchers to focus on the creative aspects of their science by providing faster, more reliable and repeatable processes with vastly lower capital costs than previously possible.
Differentiators: Transparency, flexibility, multiplex-ity
Multiple integrated automated devices per workcell
- Transparency: No other service provider on the planet can tell you exactly how they run an experiment on the user’s behalf. Transcriptic provides deep transparency into how users’ experiments were run by executing experiments exactly as specified and also providing retrospective diagnostic data on individual instrument performance during the experiment.
- Flexible robotics: Being a robotic cloud lab, the Transcriptic system can dynamically provision robotic resources to process samples for users. For example, the system might start the week at a scale of one plate and end the week on hundreds of plates. Users only pay for the resources they use, reaping the reproducibility and throughput benefits of robotics without any of the overhead.
- Easy multiplexing: The Transcriptic web application makes it easy as checking a box to detect an additional analyte in your sample. When it’s that easy, you can perform multiplexed quantiation of more analytes, starting to generate a more accurate picture of the phenotypic state of your sample.
Featured Service: Mesocale Discovery (MSD) Assay
The MSD assay, validated in many bioanalytical methods per U.S. FDA and EMA guidances, is offered as a service by Transcriptic. The Mesoscale Discovery Sector S 600 instrument is fully integrated with the Transcriptic robotic cloud lab.
The MSD S 600 instrument performs multiplexed detection of up to 10 analytes per well, ensuring the highest data-to-sample quantity efficiency, in immunoassays. Multiple assay panels are available from the V-Plex line, all conducted with complete automated precision by robots in the cloud. Custom panel assays are also available through the MSD U-Plex system.
Why requesters choose Transcriptic
Transcriptic, in collaboration with multiple biopharma companies and non-academic laboratories, has delivered many peer-reviewed publications and conference presentations.
Transcriptic presented one interesting study at SynBioBeta 2016. In collaboration with EpiBiome, Transcriptic’s automated platform provided a robust, reproducible and high-throughput method for on-demand microbiome characterization. This workflow captured sample prep through NGS and sequencing analysis in 7-10 days, allowing for fast, iterative cycles of microbiome screening.
Visit the Transcriptic storefront today to request some quotes!
September 18, 2017 | Posted by Team in Outsourcing Trends |
Contract review, service provider qualification, and security of intellectual property among major concerns for biotech and pharma leaders surveyed at 2017 industry conferences
PALO ALTO, Calif.– More than 100 biotechnology and drug development leaders who responded to surveys conducted during industry conferences earlier this year reported a wide range of barriers to the outsourcing of research and development (R&D) services, including the contracts review process, intellectual property (IP) security concerns, and service provider qualification. The surveys were conducted by Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), during the 2017 Biotechnology Innovation Organization (BIO) International Convention and 2017 Drug Industry Association (DIA) Global Annual Meeting.
More than 75 percent of Science Exchange survey respondents ranked the following concerns as barriers (a significant barrier or somewhat of a barrier) to the outsourcing of R&D services:
- Having contracts reviewed and signed
- Security of IP;
- Identifying service providers with required expertise;
- Qualifying service providers; and
- Negotiating pricing.
Time management related to R&D outsourcing was also reported as having a significant impact on these R&D leaders, with over 40 percent of those responding to the survey indicating they spent more than 20 hours to onboard each new outsourcing partner, from the request for proposal process, through contracting and start of the project. Finally, further demonstrating the impact of the time spent on administrative tasks related to outsourcing, more than 75 percent of survey respondents reported that the “hassle” of bringing on a new partner has previously led them to choose an existing vendor rather than seek out a more qualified option.
“The results of this survey echo the same concerns we heard from the leading biotech and pharma companies who now rely on Science Exchange to help them efficiently manage their outsourced R&D services,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “In review of enterprise clients’ experiences, we find that our Science Exchange clients save thousands of work hours each year on procurement, business operations, contracting and legal resources, and administrative tasks related to outsourcing — time that can instead be spent in discovery. It’s gratifying to see that we’re able to fulfill our goal to support the scientific discovery process by removing barriers to innovation for our clients.”
See how your organization could streamline outsourced R&D through Science Exchange — request a demo of our platforms for enterprise clients.
Follow Us